Atlas Trials

Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD

Clinical trial NCT02161575 · COMPLETED

Trial details

NCT number
NCT02161575
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration
Start date
2014-08-28
Primary completion
2017-09-14
Enrollment
103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.